NDAORALTABLETPriority Review
Approved
Apr 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Choloxin (dextrothyroxine sodium) is an oral tablet containing the dextro-enantiomer of thyroxine, approved in 1967 as a thyroid hormone-based therapeutic. The mechanism of action and specific indications are not fully characterized in available data. This is a legacy small molecule product with historical roots in endocrinology.
LOE Approaching
This legacy product is approaching loss of exclusivity with minimal current market activity, suggesting a small, maintenance-focused team structure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Choloxin offers limited career growth due to zero linked job openings and approaching loss of exclusivity. Roles are focused on defending market share and managing profitable decline rather than launch or expansion activities.
Brand ManagerField Sales Representative
Worked on CHOLOXIN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.